abt-981
mAbexperimentalMulti-specific
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01668511)
Timeline
Indications
Mechanism of action
- Interleukin-1 betaINHIBITOR
Interleukin-1 beta inhibitor
- Interleukin-1 alphaINHIBITOR
Interleukin-1 alpha inhibitor
- Interleukin-1 betaImmunity, passive
IL1B immunity, passive
- Interleukin-1 alphaImmunity, passive
IL1A immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594518 ↗
Also known as
- abt-981
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06865105 | Phase 2 | Jun 30, 2025 | AbbVie |
| NCT06972446 | Phase 2 | Jun 20, 2025 | AbbVie |
| NCT06718101 | Phase 2 | Dec 30, 2024 | AbbVie |
| NCT06548542 | Phase 2 | Sep 4, 2024 | AbbVie |
| NCT06524635 | Phase 2 | Aug 14, 2024 | AbbVie |
| NCT06468228 | Phase 3 | Jun 27, 2024 | AbbVie |
| NCT06257875 | Phase 2 | Mar 23, 2024 | AbbVie |
| NCT06067568 | Phase 1 | Sep 28, 2023 | AbbVie |
| NCT05139602 | Phase 2 | Dec 17, 2021 | AbbVie |
| NCT02087904 | Phase 2 | May 1, 2014 | AbbVie |
| NCT02384538 | Phase 2 | Jul 1, 2013 | AbbVie |
| NCT01668511 | Phase 1 | Sep 1, 2012 | AbbVie |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 12 | 12 | 3 | 2012 |
1 organizations
Page 1 / 1